AbbVie Inc. $ABBV Shares Sold by Simplicity Wealth LLC

Simplicity Wealth LLC trimmed its position in AbbVie Inc. (NYSE:ABBV) by 45.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,212 shares of the company’s stock after selling 25,039 shares during the quarter. Simplicity Wealth LLC’s holdings in AbbVie were worth $6,995,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ABBV. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie during the 2nd quarter worth approximately $36,000. Bear Mountain Capital Inc. increased its position in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the period. Finally, Delos Wealth Advisors LLC acquired a new position in AbbVie during the second quarter worth approximately $39,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ABBV. BMO Capital Markets restated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. Guggenheim upped their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Citigroup decreased their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Finally, DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Stock Up 1.0%

Shares of NYSE:ABBV opened at $216.13 on Thursday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a 50-day moving average price of $226.15 and a 200 day moving average price of $216.99. The company has a market cap of $381.98 billion, a P/E ratio of 163.73, a PEG ratio of 0.87 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is currently 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.